Full Press Release Details
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego. The presentations will be the first time Mural will share preclinical data from its IL-18 and IL-12 programs.
The details are as follows:
Interleukin-18 engineered for resistance to IL-18 binding protein (IL-18BP) and half-life extension to enhance its therapeutic potential
Session: Immune Modulation with Cytokines
Date and Time: Tuesday Apr 9, 2024, 9:00 a.m. - 12:30 p.m. PST
Location: Poster Section 4, Poster 20
Speaker/Lead Author: Mark Whitmore, Ph.D., Mural Oncology
Generation of tumor targeted self-assembling split IL-12 subunits for the treatment of cancer
Session: Immune Modulation with Cytokines
Date and Time: Tuesday Apr 9, 2024, 9:00 a.m. - 12:30 p.m. PST
Location: Poster Section 4, Poster 10
Speaker/Lead Author: Joshua Heiber, Ph.D., Mural Oncology
All posters will be made available at https://www.muraloncology.com/publications/ following the presentations.
About Mural Oncology